Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00GNW
|
||||
| Former ID |
DNC007131
|
||||
| Drug Name |
2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [528673] | ||
| Formula |
C23H23N3
|
||||
| Canonical SMILES |
CCC(CC)C1=NC2=C(N1)C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4
|
||||
| InChI |
1S/C23H23N3/c1-3-16(4-2)22-25-21-19(17-11-7-5-8-12-17)15-20(24-23(21)26-22)18-13-9-6-10-14-18/h5-16H,3-4H2,1-2H3,(H,24,25,26)
|
||||
| InChIKey |
GPQRSDCKVYJMOH-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Adenosine A2b receptor | Target Info | Inhibitor | [528673] | |
| Adenosine A2a receptor | Target Info | Inhibitor | [528673] | ||
| Adenosine A1 receptor | Target Info | Inhibitor | [528673] | ||
| Adenosine A3 receptor | Target Info | Inhibitor | [528673] | ||
| KEGG Pathway | Rap1 signaling pathway | ||||
| Calcium signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Alcoholismhsa04015:Rap1 signaling pathway | |||||
| cAMP signaling pathway | |||||
| Parkinson's disease | |||||
| Alcoholismhsa04022:cGMP-PKG signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Morphine addiction | |||||
| Pathway Interaction Database | C-MYB transcription factor networkhif2pathway:HIF-2-alpha transcription factor network | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.